公开(公告)号：US20230406902A1

公开(公告)日：2023-12-21

申请号：US18316893

申请日：2023-05-12

Applicant: BioNTech SE ,  Tron-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz ,  JPT Peptide Technologies GmbH

Inventor： Ugur Sahin ,  Matin Daneschdar ,  Hans-Ulrich Schmoldt ,  Laura-Marie Kring (née Plum) ,  Markus Fiedler ,  Ulf Reimer ,  Karsten Schnatbaum

IPC: C07K14/705 ,  G01N33/53 ,  C07K7/64 ,  A61K38/12 ,  A61K38/08 ,  A61K39/00 ,  G01N33/574

CPC classification number: C07K14/705 ,  G01N33/5308 ,  C07K7/64 ,  A61K38/12 ,  A61K38/08 ,  A61K39/0005 ,  G01N33/57492 ,  G01N2500/04 ,  G01N2333/705 ,  G01N2500/02

Abstract: The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.

公开(公告)号：US20190094246A1

公开(公告)日：2019-03-28

申请号：US16083440

申请日：2017-03-07

Applicant: AMONETA DIAGNOSTICS SAS ,  JPT PEPTIDE TECHNOLOGIES GMBH ,  CNRS - Centre National de la Recherche Scientifiqu ,  Université de Strasbourg

Inventor： Saliha MOUSSAOUI ,  Dirk WILDEMANN ,  Holger WENSCHUH ,  Karsten SCHNATBAUM ,  Gilles ULRICH ,  Jean DE BARRY ,  Corinne MBEBI-LIEGEOIS ,  Hueseyin FIRAT

IPC: G01N33/68 ,  C07K14/47 ,  C07F5/02

Abstract: The present invention relates to a biomarker, and/or methods including a non-invasive in vitro method using this biomarker, for diagnosing or monitoring the development or the progression of Alzheimer's disease (AD) or a disease or disorder associated with β-amyloid peptide (Aβ) deposition or tau hyperphosphorylation or a disease or disorder characterized by a proteinopathy implicating abnormalities in protein kinase C (PKC).

公开(公告)号：US10858415B2

公开(公告)日：2020-12-08

申请号：US15113981

申请日：2014-01-29

Applicant: BioNTech AG ,  TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg—Universitat Mainz gemeinnutzige GmbH ,  Universitatsmedizin der Johannes Gutenberg—Universitat Mainz ,  JPT Peptide Technologies GmbH

Inventor： Ugur Sahin ,  Matin Daneschdar ,  Hans-Ulrich Schmoldt ,  Laura-Marie Kring (née Plum) ,  Markus Fiedler ,  Ulf Reimer ,  Karsten Schnatbaum

IPC: A61K38/08 ,  A61K38/12 ,  C07K5/00 ,  A61K38/04 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00 ,  C07K14/705 ,  C07K7/64 ,  A61K39/00 ,  G01N33/53 ,  G01N33/574

Abstract: The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.

公开(公告)号：US20200031898A1

公开(公告)日：2020-01-30

申请号：US16595440

申请日：2019-10-07

Applicant: BioNTech AG ,  TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz ,  Universitatsmedizin der Johannes Gutenberg-Universitat Mainz ,  JPT Peptide Technologies GmbH

Inventor： Ugur Sahin ,  Matin Daneschdar ,  Hans-Ulrich Schmoldt ,  Laura-Marie Kring (née Plum) ,  Markus Fiedler ,  Ulf Reimer ,  Karsten Schnatbaum

IPC: C07K14/705 ,  G01N33/53 ,  A61K39/00 ,  G01N33/574

Abstract: The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.

公开(公告)号：US20160347815A1

公开(公告)日：2016-12-01

申请号：US15113981

申请日：2014-01-29

Applicant: BIONTECH AG ,  TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERS ,  UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG- UNIVERSITÄT MAINZ ,  JPT PEPTIDE TECHNOLOGIES GMBH

Inventor： Ugur Sahin ,  Matin Daneschdar ,  Hans-Ulrich Schmoldt ,  Laura Marie Plum ,  Markus Fiedler ,  Ulf Reimer ,  Karsten Schnatbaum

IPC: C07K14/705 ,  G01N33/53 ,  A61K39/00 ,  G01N33/574

CPC classification number: C07K14/705 ,  A61K39/0005 ,  G01N33/5308 ,  G01N33/57492 ,  G01N2333/705 ,  G01N2500/02 ,  G01N2500/04

Abstract: The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.

Abstract translation: 本发明提供模拟整合的跨膜蛋白克劳丁18.2（CLDN18.2）的抗原决定簇的分子。 这些分子与CLDN18.2竞争结合CLDN18.2结合结构域，例如。 抗体的CLDN18.2结合结构域，并且能够检测针对CLDN18.2的抗体。 本发明的模拟表位可用于产生或抑制动物和优选人类的免疫应答。 此外，它们可以用于检测在生物样品中包含CLDN18.2结合结构域的试剂以及用于包含CLDN18.2结合结构域的纯化剂的目的。

公开(公告)号：US20160223562A1

公开(公告)日：2016-08-04

申请号：US15074214

申请日：2016-03-18

Applicant: JPT Peptide Technologies GmbH

Inventor： Johannes Zerweck ,  Mike Schutkowski ,  Holger Wenschuh

IPC: G01N33/68

CPC classification number: G01N33/6848 ,  C07K2/00 ,  G01N33/68 ,  G01N2458/15 ,  G01N2560/00

Abstract: The present invention is related to a method for preparing an internal peptide standard, comprising a) providing a first tag, and b) coupling of a first peptide to the first tag, whereby the first peptide comprises an amino acid sequence, or a) providing a first tag and b) coupling to the first tag the amino acids forming the first peptide comprising an amino acid sequence, whereby the C-terminal end of the amino acid sequence of the first peptide corresponds to the C-terminal end generated by a sequence-specific hydrolysis of an amide bond, ester bond or thioester bond preferably of an amide bond of a peptide.

公开(公告)号：US20160153994A1

公开(公告)日：2016-06-02

申请号：US14896261

申请日：2014-06-10

Applicant: JPT Peptide Technologies GmbH ,  Chartié-Universitatsmedizin Berlin (Charité)

Inventor： Carmen Scheibenbogen ,  Hans-Dieter Volk ,  Josef Priller ,  Klemens Ruprecht ,  Ulf Reimer ,  Holger Wenschuh

IPC: G01N33/569 ,  C12Q1/70

CPC classification number: G01N33/56994 ,  C12Q1/705 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N2333/05 ,  G01N2469/10

Abstract: The present invention relates to an in vitro method for diagnosing Chronic Fatigue Syndrome by determining the presence, absence or the amount of at least one marker characteristic of an Epstein-Barr virus (EBV) infection in a sample obtained from the body of an individual. Specifically, the marker characteristic of EBV infection is selected from the group consisting of EBNA1, EBNA3, EBNA4, EBNA6, BZLF1, LMP1 and VP26. Furthermore, the invention relates to a device for the diagnosis of Chronic Fatigue Syndrome, wherein the device comprises a solid phase having immobilized thereon at least one marker or protein fragment thereof, wherein the marker is selected from the group consisting of EBNA1, EBNA3, EBNA4, EBNA6, BZLF1, LMP1 and VP26. In addition, the invention relates to the use of at least one marker or a protein fragment thereof for diagnosis of Chronic Fatigue, wherein the marker is selected from the group consisting of EBNA1 EBNA3, EBNA4, EBNA6, BZLF1, LMP1 and VP26.

Abstract translation: 本发明涉及一种用于诊断慢性疲劳综合症的体外方法，其通过确定从个体的体内获得的样品中至少一种爱泼斯坦 - 巴尔病毒（EBV）感染特征的特征的存在，不存在或数量。 具体地，EBV感染的标记特征选自EBNA1，EBNA3，EBNA4，EBNA6，BZLF1，LMP1和VP26。 此外，本发明涉及用于诊断慢性疲劳综合征的装置，其中该装置包括其上固定有至少一个标记物或蛋白质片段的固相，其中所述标记选自EBNA1，EBNA3，EBNA4 ，EBNA6，BZLF1，LMP1和VP26。 此外，本发明涉及至少一种标志物或其蛋白质片段用于诊断慢性疲劳的用途，其中所述标志物选自EBNA1 EBNA3，EBNA4，EBNA6，BZLF1，LMP1和VP26。